Get the Stockscreener App
2.40
0.00%
0.00
Proqr Therapeutics N V Stock (PRQR) Latest News
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Rating of "Buy" from Analysts - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Ballentine Partners LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Offer Predictions for PRQR FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on PRQR FY2025 Earnings - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update - MarketBeat
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock poised for growth - Investing.com
Oppenheimer Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Receives $7.60 Consensus Target Price from Analysts - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat
BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics' SWOT analysis: RNA-editing stock poised for clinical leap - Investing.com
ProQR Therapeutics’ (PRQR) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
ProQR Therapeutics’ (PRQR) Buy Rating Reiterated at HC Wainwright - Defense World
ProQR Therapeutics (NASDAQ:PRQR shareholders incur further losses as stock declines 21% this week, taking five-year losses to 70% - Simply Wall St
Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding - Simply Wall St
ProQR Therapeutics (NASDAQ:PRQR) Earns “Buy” Rating from Chardan Capital - Defense World
Leiden-based biotech company ProQR bags €7.7M - Silicon Canals
ProQR shares hold price target, buy rating on RNA tech optimism - Investing.com
JMP Securities Reiterates Market Outperform Rating for ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Receives "Buy" Rating from Chardan Capital - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given "Buy" Rating at HC Wainwright - MarketBeat
ProQR Therapeutics announces $8.1M in new funding from RSRT - Yahoo Finance
RNA specialist ProQR Therapeutics NV bags US$8.1m funding - European Biotechnology News
ProQR secures $9.1M for Rett syndrome trial By Investing.com - Investing.com South Africa
ProQR secures $9.1M for Rett syndrome trial - Investing.com India
ProQR Therapeutics Announces $8.1 Million in New Funding - GlobeNewswire
ProQR Secures $8.1M Funding Boost to Advance Revolutionary Rett Syndrome Treatment - StockTitan
ProQR Therapeutics' SWOT analysis: RNA editing stock faces pivotal clinical phase - Investing.com
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist - The Manila Times
ProQR Therapeutics Strengthens RNA Editing Leadership with Key ADAR Expert Appointment - StockTitan
ProQR Therapeutics price target raised to $8 from $5 at JMP Securities - Yahoo Finance
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.com - Defense World
OneDigital Investment Advisors LLC Boosts Holdings in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics NV (MEX:PRQR) Earnings Yield % : N/A% (As of Nov. 21, 2024) - GuruFocus.com
RNA Editing Market Top Companies StudyProQR Therapeutics NV, - openPR
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageTime to Sell? - MarketBeat
ProQR Therapeutics NV (MEX:PRQR) 50-Day SMA : MXN35.82 (As of Nov. 20, 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) 3-Year EBITDA Growth Rate : 31.80% (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) 3-Year Book Growth Rate : -26.20% (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (MEX:PRQR) Cash Flow from Financing : MXN-38.6 Mil (TTM As of Jun. 2024) - GuruFocus.com
Chardan Capital Issues Pessimistic Outlook for PRQR Earnings - Defense World
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):